KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Common Equity for 6 consecutive years, with $964.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 10.58% year-over-year to $964.0 million, compared with a TTM value of $964.0 million through Sep 2025, down 10.58%, and an annual FY2024 reading of $1.1 billion, down 8.35% over the prior year.
  • Common Equity was $964.0 million for Q3 2025 at AbCellera Biologics, down from $1.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q3 2022 and bottomed at $953.4 million in Q3 2021.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • The sharpest move saw Common Equity soared 1043.67% in 2021, then fell 10.58% in 2025.
  • Year by year, Common Equity stood at $1.0 billion in 2021, then grew by 20.23% to $1.2 billion in 2022, then fell by 6.56% to $1.2 billion in 2023, then decreased by 8.35% to $1.1 billion in 2024, then decreased by 8.72% to $964.0 million in 2025.
  • Business Quant data shows Common Equity for ABCL at $964.0 million in Q3 2025, $1.0 billion in Q2 2025, and $1.0 billion in Q1 2025.